- Home
- ANL vs DCF Comparison
ANL vs DCF Comparison
Compare ANL & DCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- DCF
- Stock Information
- Founded
- ANL 2004
- DCF 2014
- Country
- ANL Cayman Islands
- DCF United States
- Employees
- ANL 127
- DCF N/A
- Industry
- ANL
- DCF Finance/Investors Services
- Sector
- ANL
- DCF Finance
- Exchange
- ANL Nasdaq
- DCF Nasdaq
- Market Cap
- ANL 115.1M
- DCF 137.0M
- IPO Year
- ANL 2023
- DCF N/A
- Fundamental
- Price
- ANL $3.12
- DCF $9.24
- Analyst Decision
- ANL Strong Buy
- DCF
- Analyst Count
- ANL 2
- DCF 0
- Target Price
- ANL $9.00
- DCF N/A
- AVG Volume (30 Days)
- ANL 29.1K
- DCF 33.2K
- Earning Date
- ANL 08-08-2024
- DCF 01-01-0001
- Dividend Yield
- ANL N/A
- DCF 5.25%
- EPS Growth
- ANL N/A
- DCF N/A
- EPS
- ANL N/A
- DCF N/A
- Revenue
- ANL $5,000,000.00
- DCF N/A
- Revenue This Year
- ANL N/A
- DCF N/A
- Revenue Next Year
- ANL N/A
- DCF N/A
- P/E Ratio
- ANL N/A
- DCF N/A
- Revenue Growth
- ANL N/A
- DCF N/A
- 52 Week Low
- ANL $1.85
- DCF $7.25
- 52 Week High
- ANL $17.48
- DCF $8.67
- Technical
- Relative Strength Index (RSI)
- ANL 64.09
- DCF 58.78
- Support Level
- ANL $2.88
- DCF $9.19
- Resistance Level
- ANL $3.50
- DCF $9.25
- Average True Range (ATR)
- ANL 0.41
- DCF 0.05
- MACD
- ANL 0.12
- DCF 0.00
- Stochastic Oscillator
- ANL 60.19
- DCF 92.31
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About DCF BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund Inc.
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund Inc is a diversified closed-end management investment company. Its investment objectives are to seek high current income and to return at least the Fund's original NAV to holders of record of common shares on or about the termination date.